ATE437655T1 - Humanisierte anti-erbb2 antikörper und behandlung mit anti-erbb2 antikörper - Google Patents

Humanisierte anti-erbb2 antikörper und behandlung mit anti-erbb2 antikörper

Info

Publication number
ATE437655T1
ATE437655T1 AT00943115T AT00943115T ATE437655T1 AT E437655 T1 ATE437655 T1 AT E437655T1 AT 00943115 T AT00943115 T AT 00943115T AT 00943115 T AT00943115 T AT 00943115T AT E437655 T1 ATE437655 T1 AT E437655T1
Authority
AT
Austria
Prior art keywords
erbb2 antibodies
treatment
humanized anti
humanized
erbb2
Prior art date
Application number
AT00943115T
Other languages
German (de)
English (en)
Inventor
Camellia Adams
Leonard Presta
Mark Sliwkowsky
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22495168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE437655(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE437655T1 publication Critical patent/ATE437655T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Packages (AREA)
AT00943115T 1999-06-25 2000-06-23 Humanisierte anti-erbb2 antikörper und behandlung mit anti-erbb2 antikörper ATE437655T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14131699P 1999-06-25 1999-06-25
PCT/US2000/017366 WO2001000245A2 (en) 1999-06-25 2000-06-23 HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES

Publications (1)

Publication Number Publication Date
ATE437655T1 true ATE437655T1 (de) 2009-08-15

Family

ID=22495168

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00943115T ATE437655T1 (de) 1999-06-25 2000-06-23 Humanisierte anti-erbb2 antikörper und behandlung mit anti-erbb2 antikörper
AT0911000A AT500848B1 (de) 1999-06-25 2000-06-23 Humanisierte anti-erbb2-antikörper

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT0911000A AT500848B1 (de) 1999-06-25 2000-06-23 Humanisierte anti-erbb2-antikörper

Country Status (32)

Country Link
EP (2) EP2112167A3 (h)
JP (2) JP4283474B2 (h)
KR (2) KR100850389B1 (h)
CN (4) CN101121021B (h)
AR (1) AR024464A1 (h)
AT (2) ATE437655T1 (h)
AU (2) AU784045B2 (h)
BE (1) BE2013C020I2 (h)
BR (2) BRPI0012198B8 (h)
CA (2) CA2727172A1 (h)
CH (1) CH694589A5 (h)
CY (2) CY1109525T1 (h)
CZ (1) CZ299702B6 (h)
DE (2) DE10084743T1 (h)
DK (1) DK1189641T5 (h)
ES (1) ES2329437T3 (h)
FR (1) FR13C0016I2 (h)
GB (1) GB2368796B (h)
GE (1) GEP20104998B (h)
HU (1) HU226742B1 (h)
IL (3) IL146954A0 (h)
LU (1) LU92164I2 (h)
MX (1) MXPA01013458A (h)
NO (3) NO328377B1 (h)
NZ (2) NZ531426A (h)
PL (2) PL204629B1 (h)
PT (1) PT1189641E (h)
RU (2) RU2270029C2 (h)
SI (3) SI2283867T1 (h)
TR (1) TR200103756T2 (h)
WO (1) WO2001000245A2 (h)
ZA (2) ZA200109786B (h)

Families Citing this family (236)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
ES2536676T3 (es) * 1999-06-25 2015-05-27 Genentech, Inc. Métodos de tratamiento usando conjugados de anticuerpo anti-ErbB-maitansinoide
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
AU784045B2 (en) * 1999-06-25 2006-01-19 Genentech Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US6825333B1 (en) 1999-08-20 2004-11-30 Chiron Corporation EGFH2 genes and gene products
KR20020027587A (ko) 1999-08-27 2002-04-13 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
JP4776843B2 (ja) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
CA2407556C (en) 2000-05-19 2011-06-21 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
EP1228766A1 (en) * 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PYK2 phosphorylation by HER3 induces tumor invasion
ES2304264A1 (es) * 2001-10-26 2008-10-01 Altarex Medical Corp. Terapia de combinacion para tratar enfermedades.
PL375033A1 (en) * 2002-04-11 2005-11-14 Amgen, Inc. Her-2 receptor tyrosine kinase molecules and uses thereof
ITTO20020340A1 (it) * 2002-04-19 2003-10-20 Biother Di Contardi Gabriella Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato.
WO2003101401A2 (en) 2002-06-03 2003-12-11 Chiron Corporation Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
AT413486B (de) * 2002-07-03 2006-03-15 Igeneon Krebs Immuntherapie Verwendung eines antikörpers gerichtet gegen lewis-antigene
NO340576B1 (no) * 2002-07-11 2017-05-15 Hoffmann La Roche Rekombinant, humanisert antistoff 2C4 (rhuMab 2C4) for anvendelse sammen med et andre, forskjellig vekstinhiberende anti-ErbB2-antistoff i en fremgangsmåte for behandling av kreft i en pasient og anvendelse derav for fremstilling av et medikament
PL214010B1 (pl) * 2002-07-15 2013-06-28 Genentech Inc Rekombinowane humanizowane przeciwcialo 2C4 i zastosowanie tego przeciwciala
PL217626B1 (pl) * 2002-07-18 2014-08-29 Helix Biopharma Corp Kompozycja farmaceutyczna do zastosowania w leczeniu raka
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
CA2872136C (en) 2002-07-18 2017-06-20 Merus B.V. Recombinant production of mixtures of antibodies
US7264800B2 (en) 2002-07-18 2007-09-04 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
AU2003248982B2 (en) 2002-08-01 2009-12-10 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7803372B2 (en) * 2002-10-08 2010-09-28 Immunomedics, Inc. Antibody therapy
WO2004054622A1 (en) * 2002-12-13 2004-07-01 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
WO2005003325A2 (en) * 2003-03-11 2005-01-13 Dana Farber Cancer Institute Inhibition of viral pathogenesis
AU2004233346B2 (en) 2003-04-23 2008-03-06 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
AT500651B9 (de) * 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
EP2395016A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
HUE050171T2 (hu) 2003-07-28 2020-11-30 Genentech Inc Protein-A kioldódásának csökkentése protein-A affinitáskromatográfia során
JP2007504164A (ja) * 2003-08-29 2007-03-01 セダーズ−シナイ メディカル センター ＰＰＡＲ−γ経路およびＨＥＲ−キナーゼ軸の調節に基づく癌および他の生理学的状態の処置のための組成物および方法
CA2539322C (en) * 2003-09-18 2016-07-12 Raven Biotechnologies, Inc. Kid3 and kid3 antibodies that bind thereto
US20080267865A1 (en) * 2003-11-28 2008-10-30 Biotech Igg Ab Targeting of Erb Antigens
RU2402568C2 (ru) * 2004-02-06 2010-10-27 МорфоСис АГ Человеческие анти-cd38-антитела и их применение
RU2273475C2 (ru) * 2004-04-06 2006-04-10 Государственное учреждение системы высшего и послевузовского профессионального образования "Сибирский государственный медицинский университет" (ГУ СВ ПО СибГМУ) Способ лечения диссеминированного колоректального рака
EP1753463A2 (en) 2004-06-01 2007-02-21 Genentech, Inc. Antibody drug conjugates and methods
GT200500155A (es) * 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
KR20190126461A (ko) 2004-07-22 2019-11-11 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP1791565B1 (en) 2004-09-23 2016-04-20 Genentech, Inc. Cysteine engineered antibodies and conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20060121044A1 (en) * 2004-12-07 2006-06-08 Genentech, Inc. Selecting patients for therapy with a her inhibitor
KR20070094928A (ko) 2005-01-21 2007-09-27 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
MX2007009889A (es) 2005-02-23 2007-09-07 Genentech Inc Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer.
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
JP2008541781A (ja) 2005-06-06 2008-11-27 ジェネンテック・インコーポレーテッド 異なる遺伝子に対するトランスジェニック動物、および遺伝子の特徴づけのためのその使用
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
US7931902B2 (en) 2005-08-15 2011-04-26 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
KR101164820B1 (ko) 2005-09-22 2012-07-12 삼성전자주식회사 디스플레이장치
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
EP1962584A2 (en) 2005-11-21 2008-09-03 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007114979A2 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
EP2082645A1 (en) 2006-04-19 2009-07-29 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
RU2436796C9 (ru) 2006-05-30 2013-12-27 Дженентек, Инк. Антитела и иммуноконъюгаты и их применения
KR20090019890A (ko) * 2006-06-05 2009-02-25 제넨테크, 인크. Ｅｇｆ 또는 ｔｇｆ-알파 수준이 상승된 암 환자의 생존 연장
RU2528884C2 (ru) 2006-08-21 2014-09-20 Ф.Хоффманн-Ля Рош Аг Лечение опухолей с помощью антитела к vegf
WO2008031531A1 (en) * 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
CA2665528C (en) * 2006-10-12 2018-01-23 The University Of Tokyo Diagnosis and treatment of cancer using anti-ereg antibody
HRP20120683T1 (hr) 2006-10-27 2012-09-30 Genentech Protutijela i imunokonjugati te njihove uporabe
WO2008109440A2 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her dimerisation inhibitor based on low her3 expression
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
PL2171090T3 (pl) 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
JP2010530437A (ja) * 2007-06-18 2010-09-09 メディミューン，エルエルシー ＥｐｈＡ２およびＥｒｂＢ２を発現する細胞の相乗的治療
EP2176295B1 (en) 2007-07-16 2014-11-19 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
SI2474557T1 (sl) 2007-07-16 2014-12-31 Genentech, Inc. Protiteles proti CD79b in imunokonjugati in postopki za uporabo
DK2565206T3 (en) 2007-10-30 2016-06-06 Genentech Inc Antibody Purification by cation exchange chromatography
WO2009068631A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
ES2437595T3 (es) 2007-12-20 2014-01-13 Novartis Ag Derivados de tiazol usados como inhibidores de la PI 3 quinasa
CA2711256C (en) 2008-01-03 2019-01-15 The Scripps Research Institute Antibody targeting through a modular recognition domain
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
AR070168A1 (es) 2008-01-31 2010-03-17 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados y metodos de uso de los mismos
BRPI0906049A8 (pt) * 2008-03-14 2018-06-26 Genentech Inc método para determinar se um câncer em um paciente é resistente ao tratamento com um agente antimitótico, método para tratar um paciente com câncer que é resistente ao agente antimitótico e método de tratamento
HUE035184T2 (en) * 2008-03-18 2018-05-02 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
DK2789684T3 (en) 2008-05-23 2017-02-20 Siwa Corp Methods and compositions for facilitating regeneration
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
WO2010030670A2 (en) 2008-09-10 2010-03-18 Genentech, Inc. Compositions and methods for the prevention of oxidative degradation of proteins
DK3903829T3 (da) 2009-02-13 2023-06-26 Immunomedics Inc Immunkonjugater med en intracellulær spaltelig binding
ES2572728T3 (es) 2009-03-20 2016-06-02 F. Hoffmann-La Roche Ag Anticuerpos anti-HER biespecíficos
MX2011010264A (es) 2009-04-01 2011-10-11 Genentech Inc Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso.
CA2757669A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-1/anti-c-met antibodies
US20120121586A1 (en) 2009-05-29 2012-05-17 Astrid Kiermaier Modulators for her2 signaling in her2 expressing patients with gastric cancer
JP5808052B2 (ja) 2009-05-29 2015-11-10 中外製薬株式会社 Ｅｇｆファミリーリガンドのアンタゴニストを成分とする医薬組成物
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
SG10201901417UA (en) 2009-08-11 2019-03-28 Genentech Inc Production of proteins in glutamine-free cell culture media
EP2464381A1 (en) * 2009-08-15 2012-06-20 F. Hoffmann-La Roche AG Anti-angiogenesis therapy for the treatment of previously treated breast cancer
EP3736338A1 (en) 2009-09-01 2020-11-11 F. Hoffmann-La Roche AG Enhanced protein purification through a modified protein a elution
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
US9096877B2 (en) 2009-10-07 2015-08-04 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
US8658175B2 (en) * 2009-10-28 2014-02-25 Abbvie Biotherapeutics Inc. Anti-EGFR antibodies and their uses
US8361744B2 (en) 2009-11-05 2013-01-29 Genentech, Inc. Methods and composition for secretion of heterologous polypeptides
NO2719708T3 (h) 2009-11-13 2018-03-24
CN102770456B (zh) 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
CA2788715C (en) * 2010-02-04 2021-06-08 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
JP5981853B2 (ja) 2010-02-18 2016-08-31 ジェネンテック， インコーポレイテッド ニューレグリンアンタゴニスト及び癌の治療におけるそれらの使用
US8609095B2 (en) 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
CA3027749A1 (en) 2010-03-22 2011-09-29 Junyan Ji Compositions and methods useful for stabilizing protein-containing formulations
JP2013525484A (ja) 2010-05-03 2013-06-20 ジェネンテック， インコーポレイテッド タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2575880B1 (en) 2010-05-27 2019-01-16 Genmab A/S Monoclonal antibodies against her2 epitope
CN107253992B (zh) 2010-05-27 2022-03-11 根马布股份公司 针对her2的单克隆抗体
DK2576580T3 (en) 2010-05-28 2016-10-17 Hoffmann La Roche LOWERING THE lactate AND INCREASE polypeptide production by downregulation of the expression of lactate dehydrogenase, and PYRUVATDEHYDROGENASEKINASE
MX336109B (es) 2010-06-03 2016-01-08 Genentech Inc Formacion de imagenes inmuno-tep de anticuerpos e inmunoconjugados y usos de lo mismo.
CN114246952B (zh) 2010-06-08 2024-11-22 基因泰克公司 半胱氨酸改造的抗体和偶联物
SI2585045T1 (sl) 2010-06-24 2019-11-29 Hoffmann La Roche Sestavki in postopki, ki vsebujejo alkilglikozide za stabilizacijo formulacij, ki vsebujejo beljakovine
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
JP5838221B2 (ja) 2010-12-21 2016-01-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト アイソフォーム濃縮抗体調製物及びこれを得る方法
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
EP2655414B1 (en) 2010-12-23 2018-08-29 Roche Diagniostics GmbH Bispecific binding agent
AU2012213080B2 (en) 2011-01-31 2014-03-27 Novartis Ag Novel heterocyclic derivatives
WO2012122378A2 (en) * 2011-03-08 2012-09-13 The Trustees Of The University Of Pennsylvania Antibody-like proteins for therapeutic and diagnostic use
CA2832389A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
CN103890007A (zh) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 神经调节蛋白抗体及其用途
FI4241849T3 (fi) 2011-10-14 2024-11-12 Hoffmann La Roche Her2:n dimerisaation estäjä pertutsumabin käyttötapoja ja sitä sisältävä tuote
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
AU2012327954B2 (en) 2011-10-28 2015-11-26 Novartis Ag Novel purine derivatives and their use in the treatment of disease
EP2797957B1 (en) 2011-11-23 2019-06-19 MedImmune, LLC Binding molecules specific for her3 and uses thereof
US20130195870A1 (en) 2011-11-30 2013-08-01 Genentech, Inc. ERBB3 Mutations In Cancer
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
CN108892706A (zh) 2011-12-22 2018-11-27 弗·哈夫曼-拉罗切有限公司 使用离子交换膜层析改进下游蛋白质纯化步骤的方法
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
KR20140117644A (ko) 2012-01-31 2014-10-07 스미스클라인 비이참 (코르크) 리미티드 암을 치료하는 방법
EP2638916A1 (en) 2012-03-16 2013-09-18 Covagen AG Novel binding molecules with antitumoral activity
KR20140148388A (ko) 2012-03-27 2014-12-31 제넨테크, 인크. Her3 억제제와 관련된 진단 및 치료
ES2740749T3 (es) 2012-04-20 2020-02-06 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
KR101505157B1 (ko) 2012-05-08 2015-03-24 주식회사 종근당 항―ＥｒｂＢ２ 항체 변이체
CN104349779A (zh) 2012-05-16 2015-02-11 诺华股份有限公司 Pi-3激酶抑制剂的剂量方案
WO2014083178A1 (en) 2012-11-30 2014-06-05 F. Hoffmann-La Roche Ag Identification of patients in need of pd-l1 inhibitor cotherapy
JP6231129B2 (ja) 2013-01-10 2017-11-15 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 脂肪酸シンターゼ阻害剤
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
EP2968541A4 (en) 2013-03-15 2017-02-08 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
CN104628846B (zh) 2013-11-06 2019-12-06 三生国健药业（上海）股份有限公司 重组蛋白质的纯化方法
PL3480215T3 (pl) 2013-11-19 2021-12-13 Remegen Co., Ltd. Przeciwciało anty-HER2 i jego koniugat
RS66775B1 (sr) * 2013-11-27 2025-05-30 Zymeworks Bc Inc Bispecifični antigen-vezujući konstrukti koji targetiraju her2
KR20160095035A (ko) 2013-12-06 2016-08-10 노파르티스 아게 알파-이소형 선택성 포스파티딜이노시톨 3-키나제 억제제를 위한 투여 요법
PL3101032T3 (pl) 2014-01-31 2019-07-31 Daiichi Sankyo Company, Limited Koniugat przeciwciało anty-HER2-lek
US20160361309A1 (en) 2014-02-26 2016-12-15 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer patients responding to ezh2 inhibitor gsk126
AU2015229035B2 (en) 2014-03-14 2021-08-05 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
TW201542594A (zh) 2014-04-11 2015-11-16 Medimmune Llc 雙特異性ｈｅｒ２抗體
WO2016040856A2 (en) 2014-09-12 2016-03-17 Genentech, Inc. Cysteine engineered antibodies and conjugates
CN107001459B (zh) 2014-09-19 2021-11-23 Siwa有限公司 用于治疗炎症和自身免疫紊乱的抗age抗体
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
WO2016082044A1 (en) 2014-11-27 2016-06-02 Zymeworks Inc. Methods of using bispecific antigen-binding constructs targeting her2
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
KR101515535B1 (ko) 2015-01-28 2015-05-06 주식회사 종근당 항―ＥｒｂＢ２ 항체 변이체
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
US11028182B2 (en) 2015-05-13 2021-06-08 Zymeworks Inc. Antigen-binding constructs targeting HER2
WO2017025871A1 (en) 2015-08-07 2017-02-16 Glaxosmithkline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
CN108431044A (zh) * 2015-10-13 2018-08-21 Siwa有限公司 抗age抗体及其使用方法
US20180280370A1 (en) 2015-11-02 2018-10-04 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
ES2913208T3 (es) 2015-12-01 2022-06-01 Glaxosmithkline Ip Dev Ltd Tratamientos de combinación y usos y métodos de los mismos
MA44082A (fr) 2015-12-14 2018-10-24 Macrogenics Inc Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
CN105646704B (zh) * 2015-12-28 2019-11-15 广西医科大学 抗p185erbB2人鼠嵌合抗体ChAb26、乳腺特异性表达载体、转基因FVB小鼠及其制备方法
WO2018191718A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
ES2912064T3 (es) 2016-02-19 2022-05-24 Siwa Corp Método y composición para tratar el cáncer, destruir las células cancerosas metastásicas y evitar la metástasis del cáncer usando anticuerpo para productos finales de glicación avanzada (AGE)
BR112018068512A2 (pt) * 2016-03-15 2019-01-22 Merrimack Pharmaceuticals Inc métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3
KR20180133452A (ko) 2016-04-15 2018-12-14 시와 코퍼레이션 신경퇴행성 질환을 치료하기 위한 항-노화 항체
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
US11142585B2 (en) * 2016-05-12 2021-10-12 Agency For Science, Technology And Research Anti-ERBB-2 antibodies and uses thereof
JP2019518763A (ja) 2016-06-23 2019-07-04 シワ コーポレーション 様々な疾患及び障害の治療において使用するためのワクチン
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
JPWO2018066626A1 (ja) 2016-10-07 2019-07-18 第一三共株式会社 抗ｈｅｒ２抗体−薬物コンジュゲート投与による耐性癌の治療
US11273155B2 (en) 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
KR102646046B1 (ko) * 2017-01-06 2024-03-08 바이오션, 인코포레이티드 Erbb2 항체 및 이의 용도
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
AU2018224094B2 (en) 2017-02-24 2025-04-17 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
WO2018160138A1 (en) 2017-03-02 2018-09-07 Aslan Pharmaceuticals Pte Ltd Dhodh inhibitor for treating haematological cancer
AU2018227788B2 (en) 2017-03-02 2021-04-22 F. Hoffmann-La Roche Ag Adjuvant treatment of HER2-positive breast cancer
EP3600442A1 (en) 2017-03-22 2020-02-05 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
WO2018222135A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
CN107417791B (zh) * 2017-08-17 2020-09-22 合肥瀚科迈博生物技术有限公司 抗人ErbB2双特异性抗体、其制备方法及用途
KR20200044044A (ko) 2017-08-23 2020-04-28 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 제제 및 그 동결 건조 방법
US11318212B2 (en) 2017-08-31 2022-05-03 Daiichi Sankyo Company, Limited Method for producing antibody-drug conjugate
WO2019044947A1 (ja) 2017-08-31 2019-03-07 第一三共株式会社 抗体－薬物コンジュゲートの改良製造方法
CN107789631B (zh) * 2017-11-03 2021-03-16 合肥瀚科迈博生物技术有限公司 抗人ErbB2双表位抗体-药物偶联物及其应用
AU2018385409A1 (en) 2017-12-12 2020-07-02 Macrogenics Inc. Bispecific CD 16-binding molecules and their use in the treatment of disease
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
MX2020008489A (es) 2018-02-15 2020-09-25 Macrogenics Inc Dominios de union a cd3 variantes y su uso en terapias de combinacion para el tratamiento de enfermedades.
EP3560945A1 (en) 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Methods for purification of polypeptides using polysorbates
KR20250105480A (ko) 2018-05-28 2025-07-08 다이이찌 산쿄 가부시키가이샤 항 her2 항체-약물 콘쥬게이트 투여에 의한 her2 변이암의 치료
CN118512452A (zh) 2018-07-23 2024-08-20 特雷维治疗股份有限公司 慢性咳嗽、呼吸急促和呼吸困难的治疗
SG11202100653YA (en) 2018-07-25 2021-02-25 Daiichi Sankyo Co Ltd Effective method for manufacturing antibody-drug conjugate
AU2019311596A1 (en) 2018-07-27 2021-01-28 Daiichi Sankyo Company, Limited Protein recognizing drug moiety of antibody-drug conjugate
WO2020027100A1 (ja) 2018-07-31 2020-02-06 第一三共株式会社 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療
AU2019320336B2 (en) 2018-08-06 2025-06-05 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and tubulin inhibitor
CN112739826A (zh) 2018-08-23 2021-04-30 第一三共株式会社 抗体-药物缀合物的敏感性标志物
AU2019349934B2 (en) 2018-09-25 2024-12-05 Absci Corporation Protein purification methods
WO2020084503A1 (en) 2018-10-26 2020-04-30 Cadila Healthcare Limited A composition comprising antibody with reduced level of basic variants thereof
SG11202106248XA (en) 2018-12-11 2021-07-29 Daiichi Sankyo Co Ltd Combination of antibody-drug conjugate with parp inhibitor
MA54544A (fr) 2018-12-19 2021-10-27 Incyte Corp Inhibiteurs de la voie jak1 pour le traitement d'une maladie gastro-intestinale
SG11202106635WA (en) 2018-12-21 2021-07-29 Daiichi Sankyo Co Ltd Combination of antibody-drug conjugate and kinase inhibitor
BR112021014662A2 (pt) 2019-02-01 2021-09-21 Glaxosmithkline Intellectual Property Development Limited Tratamentos de combinação para o câncer que compreendem belantamab mafodotin e um anticorpo anti ox40 e usos e métodos dos mesmos
AR118536A1 (es) 2019-04-01 2021-10-20 Genentech Inc Composiciones y métodos para estabilizar formulaciones que contienen proteína
CN112007169B (zh) * 2019-05-30 2022-03-08 湖南大学 一种核酸适配体药物偶联物及其制备方法和用途
CN110205302B (zh) * 2019-06-24 2021-03-23 扬州大学 一株分泌抗麦考酚酸单克隆抗体的细胞株、其单克隆抗体及其应用
MX2021015651A (es) 2019-06-26 2022-06-14 Glaxosmithkline Ip Dev Ltd Proteinas de union a la proteina accesoria del receptor de interleucina-1 (il1rap).
CN110551214A (zh) * 2019-08-27 2019-12-10 杨澜 一种人源化抗Periostin单克隆抗体、及其制备方法和应用
MX2022008554A (es) 2020-01-10 2022-08-10 Trevi Therapeutics Inc Metodos de administracion de nalbufina.
CN115038466A (zh) 2020-01-28 2022-09-09 葛兰素史密斯克莱知识产权发展有限公司 联合治疗及其用途和方法
EP4106813A4 (en) 2020-02-21 2024-03-27 MacroGenics, Inc. CD137 BINDING MOLECULES AND THEIR USES
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
TW202216207A (zh) 2020-06-24 2022-05-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及cdk9抑制劑之組合
US20230256110A1 (en) 2020-06-24 2023-08-17 Astrazeneca Uk Limited Combination of antibody-drug conjugate and atm inhibitor
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
US20230330243A1 (en) 2020-06-24 2023-10-19 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and atr inhibitor
CA3186675A1 (en) 2020-07-20 2022-01-27 Yasuki KAMAI Combination of anti-her2 antibody-drug conjugate with her dimerization inhibitor
IL301921A (en) 2020-10-09 2023-06-01 Daiichi Sankyo Co Ltd Combination of antibody-drug conjugate and parp1 selective inhibitor
EP4245321A4 (en) 2020-11-11 2025-10-01 Daiichi Sankyo Co Ltd COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND AN ANTI-SIRPALPHA ANTIBODY
CA3241006A1 (en) 2021-11-30 2023-06-08 Daiichi Sankyo Company Limited Protease-cleavable masked antibodies
CN118434422A (zh) 2021-12-28 2024-08-02 阿斯利康(英国)有限公司 抗体-药物缀合物和rasg12c抑制剂的组合
JPWO2023153442A1 (h) 2022-02-09 2023-08-17
EP4514391A1 (en) 2022-04-27 2025-03-05 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
US20250296966A1 (en) 2022-05-11 2025-09-25 Daiichi Sankyo Company, Limited Combination of an antibody specific for a tumor antigen and a cd47 inhibitor
IL318586A (en) 2022-07-28 2025-03-01 Astrazeneca Uk Ltd Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
WO2025088496A1 (en) 2023-10-24 2025-05-01 Astrazeneca Uk Limited Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein
CN117224689B (zh) * 2023-11-16 2024-02-23 上海复宏汉霖生物技术股份有限公司 联合抗her2抗体和化疗剂治疗胃癌的用途
WO2025120513A1 (en) 2023-12-05 2025-06-12 Astrazeneca Uk Limited Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
DE3587657D1 (de) 1984-01-30 1993-12-23 Imp Cancer Res Tech Verbesserungen an wachstumsfaktoren.
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
ATE155813T1 (de) 1989-05-19 1997-08-15 Genentech Inc Her2 extrazellulare domäne
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
DE69025946T2 (de) 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
JP3208427B2 (ja) 1989-09-29 2001-09-10 オー・エス・アイ・ファーマシューテイカルズ・インコーポレイテッド ヒトの生物学的流体中のｎｅｕ関連タンパク質の検出及び定量
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
EP0625200B1 (en) 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
CA2120745A1 (en) 1992-06-30 1994-01-06 Philip G. Kasprzyk A combination of anti-erbb-2 monoclonal antibodies and method of using
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
DK0669836T3 (da) 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
CA2103323A1 (en) 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
DE69326937T2 (de) 1993-03-24 2000-12-28 Berlex Biosciences, Richmond Kombination von Antihormonale und bindende Moleküle zur Krebsbehandlung
AU6527894A (en) 1993-03-30 1994-10-24 Trustees Of The University Of Pennsylvania, The Prevention of tumors with monoclonal antibodies against (neu)
JPH09506250A (ja) 1993-11-23 1997-06-24 ジェネンテク，インコーポレイテッド Ｒｓｅと命名される蛋白チロシンキナーゼ
ES2166368T3 (es) 1993-12-24 2002-04-16 Merck Patent Gmbh Inmunoconjugados.
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
CA2207869A1 (en) 1994-12-02 1996-06-06 Chiron Corporation Method of promoting an immune response with a bispecific antibody
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
AU6113396A (en) 1995-06-14 1997-01-15 Regents Of The University Of California, The Novel high affinity human antibodies to tumor antigens
PT2275119E (pt) 1995-07-27 2013-11-21 Genentech Inc Formulação de proteína liofilizada isotónica estável
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
DE69732711T2 (de) * 1996-07-12 2006-03-16 Genentech, Inc., South San Francisco Gamma-heregulin
EP0918746B1 (en) * 1996-08-12 2003-04-09 Celgene Corporation Immunotherapeutic agents and their use in the reduction of cytokine levels
EP0931147A1 (en) * 1996-10-18 1999-07-28 Genentech, Inc. ANTI-ErbB2 ANTIBODIES
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1999019488A1 (en) 1997-10-15 1999-04-22 Children's Medical Center Corporation Novel human egf receptors and use thereof
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
WO2000069460A1 (en) * 1999-05-14 2000-11-23 Genentech, Inc. TREATMENT WITH ANTI-ErbB2 ANTIBODIES
KR100754049B1 (ko) * 1999-06-25 2007-08-31 제넨테크, 인크. 전립선암을 치료하기 위한 약제 제조에 사용되는 항-ErbB2 항체 및 조성물
AU784045B2 (en) * 1999-06-25 2006-01-19 Genentech Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
ES2536676T3 (es) * 1999-06-25 2015-05-27 Genentech, Inc. Métodos de tratamiento usando conjugados de anticuerpo anti-ErbB-maitansinoide
KR20020027587A (ko) * 1999-08-27 2002-04-13 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법

Also Published As

Publication number Publication date
CZ299702B6 (cs) 2008-10-22
NO20016329D0 (no) 2001-12-21
JP4283474B2 (ja) 2009-06-24
AR024464A1 (es) 2002-10-02
BR0012198A (pt) 2002-04-02
NO20016329L (no) 2002-02-25
NO328377B1 (no) 2010-02-08
KR20020068264A (ko) 2002-08-27
SI2283866T1 (sl) 2015-07-31
CY2013010I2 (el) 2015-08-05
MXPA01013458A (es) 2002-07-30
WO2001000245A2 (en) 2001-01-04
LU92164I2 (fr) 2013-05-07
CN1370082A (zh) 2002-09-18
CN101121021A (zh) 2008-02-13
GB0200506D0 (en) 2002-02-27
CH694589A5 (de) 2005-04-15
CN101121021B (zh) 2011-12-07
NO336040B1 (no) 2015-04-27
HUP0201695A3 (en) 2005-06-28
HK1044888A1 (en) 2002-11-08
SI1189641T1 (sl) 2009-12-31
CN101518653A (zh) 2009-09-02
CN101121750A (zh) 2008-02-13
AU2005242195B2 (en) 2009-06-11
NZ516830A (en) 2004-07-30
HU226742B1 (en) 2009-08-28
SI2283867T1 (sl) 2014-07-31
NZ531426A (en) 2005-10-28
AU784045B2 (en) 2006-01-19
HUP0201695A2 (en) 2002-09-28
PL204629B1 (pl) 2010-01-29
PT1189641E (pt) 2009-11-04
GEP20104998B (en) 2010-06-10
AT500848A1 (de) 2006-04-15
BR122014028365B1 (pt) 2020-01-28
ES2329437T3 (es) 2009-11-26
BRPI0012198B1 (pt) 2016-12-20
JP2009142280A (ja) 2009-07-02
RU2005132788A (ru) 2007-04-27
CA2376596C (en) 2009-10-06
JP2003503366A (ja) 2003-01-28
FR13C0016I2 (fr) 2014-05-16
KR100850389B1 (ko) 2008-08-04
RU2430739C2 (ru) 2011-10-10
FR13C0016I1 (h) 2013-04-12
CA2727172A1 (en) 2001-01-04
CA2376596A1 (en) 2001-01-04
PL352321A1 (en) 2003-08-11
CN100340575C (zh) 2007-10-03
CY1109525T1 (el) 2014-08-13
GB2368796B (en) 2004-08-04
BE2013C020I2 (h) 2019-08-21
EP2112167A3 (en) 2010-12-22
IL146954A (en) 2009-09-22
AT500848B1 (de) 2008-01-15
DK1189641T3 (da) 2009-11-16
TR200103756T2 (tr) 2002-06-21
IL146954A0 (en) 2002-08-14
EP1189641B1 (en) 2009-07-29
RU2430739C9 (ru) 2015-12-20
GB2368796A (en) 2002-05-15
DK1189641T5 (da) 2011-04-11
RU2270029C2 (ru) 2006-02-20
ZA200109786B (en) 2002-11-28
BR122014028365B8 (pt) 2021-07-06
CN101518653B (zh) 2015-08-19
EP2112167A2 (en) 2009-10-28
WO2001000245A3 (en) 2001-10-25
KR20070094993A (ko) 2007-09-27
NO2013005I2 (no) 2013-03-12
ZA200110263B (en) 2003-02-26
KR100797308B1 (ko) 2008-01-23
EP1189641A2 (en) 2002-03-27
BRPI0012198B8 (pt) 2021-05-25
DE10084743T1 (de) 2002-08-14
AU5763200A (en) 2001-01-31
PL203326B1 (pl) 2009-09-30
AU2005242195A1 (en) 2006-01-12
DE60042648D1 (de) 2009-09-10
NO20091792L (no) 2002-02-25
NO2013005I1 (no) 2013-04-02
CZ20014596A3 (cs) 2003-02-12
IL197359A0 (en) 2011-07-31
CY2013010I1 (el) 2015-08-05

Similar Documents

Publication Publication Date Title
ATE437655T1 (de) Humanisierte anti-erbb2 antikörper und behandlung mit anti-erbb2 antikörper
NO20002957L (no) Behandling med anti-ErbB2-antistoffer
EP1071458A4 (en) HUMANIZED ANTIBODIES AND CORRESPONDING USES THEREOF
NO20012160D0 (no) Anordning for behandling av makulös degenerering
DE60045386D1 (de) Gerät zur thermischen behandlung von bandscheiben
DE60001421D1 (de) Behandlung von abgas
ATE415979T1 (de) Behandlung mit anti-erbb2 antikörpern
EE200000470A (et) Inimese CD40-vastased antikehad
ATE293610T1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE293447T1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
CY2012002I2 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
ATE500830T1 (de) Behandlung von krebs beim menschen mit et743
DE60045260D1 (de) Übergangsfeldeffekttransistor und seine herstellungsmethode
DE60023454D1 (de) Lagenmaterialen mit tensid-modifizierten chelatbildern behandelt
ATE298569T1 (de) Virus behandlung
DE60021360D1 (de) Vegf angiogenische wachstumsfaktoren zur behandlung von peripheren neuropathie
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE60011060D1 (de) Virus behandlung
DK1493442T3 (da) Reboxetin til behandling af perifer neuropati
DE69912763D1 (de) Behandlungsanlage
DE69528372D1 (de) Orale behandlung
DE69915595D1 (de) Abwasserbehandlung, trägermaterial dafür und seine hestellung
SE9903421D0 (sv) Behandlingsförfarande
DK199800272U3 (da) Renseanlæg

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1189641

Country of ref document: EP